298 related articles for article (PubMed ID: 20735415)
1. Therapeutic potential of targeting group III metabotropic glutamate receptors in the treatment of Parkinson's disease.
Duty S
Br J Pharmacol; 2010 Sep; 161(2):271-87. PubMed ID: 20735415
[TBL] [Abstract][Full Text] [Related]
2. Group III and subtype 4 metabotropic glutamate receptor agonists: discovery and pathophysiological applications in Parkinson's disease.
Amalric M; Lopez S; Goudet C; Fisone G; Battaglia G; Nicoletti F; Pin JP; Acher FC
Neuropharmacology; 2013 Mar; 66():53-64. PubMed ID: 22664304
[TBL] [Abstract][Full Text] [Related]
3. Synergy between L-DOPA and a novel positive allosteric modulator of metabotropic glutamate receptor 4: implications for Parkinson's disease treatment and dyskinesia.
Bennouar KE; Uberti MA; Melon C; Bacolod MD; Jimenez HN; Cajina M; Kerkerian-Le Goff L; Doller D; Gubellini P
Neuropharmacology; 2013 Mar; 66():158-69. PubMed ID: 22491024
[TBL] [Abstract][Full Text] [Related]
4. Metabotropic glutamate receptors as therapeutic targets in Parkinson's disease: An update from the last 5 years of research.
Litim N; Morissette M; Di Paolo T
Neuropharmacology; 2017 Mar; 115():166-179. PubMed ID: 27055772
[TBL] [Abstract][Full Text] [Related]
5. Symptomatic and neuroprotective effects following activation of nigral group III metabotropic glutamate receptors in rodent models of Parkinson's disease.
Austin PJ; Betts MJ; Broadstock M; O'Neill MJ; Mitchell SN; Duty S
Br J Pharmacol; 2010 Aug; 160(7):1741-53. PubMed ID: 20649576
[TBL] [Abstract][Full Text] [Related]
6. Targeting metabotropic glutamate receptors (mGluRs) in Parkinson's disease.
Amalric M
Curr Opin Pharmacol; 2015 Feb; 20():29-34. PubMed ID: 25462289
[TBL] [Abstract][Full Text] [Related]
7. Targeting group III metabotropic glutamate receptors produces complex behavioral effects in rodent models of Parkinson's disease.
Lopez S; Turle-Lorenzo N; Acher F; De Leonibus E; Mele A; Amalric M
J Neurosci; 2007 Jun; 27(25):6701-11. PubMed ID: 17581957
[TBL] [Abstract][Full Text] [Related]
8. Changes in metabotropic glutamate receptor 1-8 gene expression in the rodent basal ganglia motor loop following lesion of the nigrostriatal tract.
Messenger MJ; Dawson LG; Duty S
Neuropharmacology; 2002 Aug; 43(2):261-71. PubMed ID: 12213280
[TBL] [Abstract][Full Text] [Related]
9. Metabotropic glutamate receptor 4 (mGlu4)-positive allosteric modulators for the treatment of Parkinson's disease: historical perspective and review of the patent literature.
Lindsley CW; Hopkins CR
Expert Opin Ther Pat; 2012 May; 22(5):461-81. PubMed ID: 22506633
[TBL] [Abstract][Full Text] [Related]
10. Allosteric modulation of the group III mGlu4 receptor provides functional neuroprotection in the 6-hydroxydopamine rat model of Parkinson's disease.
Betts MJ; O'Neill MJ; Duty S
Br J Pharmacol; 2012 Aug; 166(8):2317-30. PubMed ID: 22404342
[TBL] [Abstract][Full Text] [Related]
11. Subtype selective antagonism of substantia nigra pars compacta Group I metabotropic glutamate receptors protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo.
Vernon AC; Zbarsky V; Datla KP; Croucher MJ; Dexter DT
J Neurochem; 2007 Nov; 103(3):1075-91. PubMed ID: 17714448
[TBL] [Abstract][Full Text] [Related]
12. Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease.
Mela F; Marti M; Dekundy A; Danysz W; Morari M; Cenci MA
J Neurochem; 2007 Apr; 101(2):483-97. PubMed ID: 17359492
[TBL] [Abstract][Full Text] [Related]
13. Interaction of adenosine receptors with other receptors from therapeutic perspective in Parkinson's disease.
Morin N; Di Paolo T
Int Rev Neurobiol; 2014; 119():151-67. PubMed ID: 25175965
[TBL] [Abstract][Full Text] [Related]
14. Metabotropic glutamate receptors in Parkinson's disease.
Kwan C; Kang W; Kim E; Belliveau S; Frouni I; Huot P
Int Rev Neurobiol; 2023; 168():1-31. PubMed ID: 36868628
[TBL] [Abstract][Full Text] [Related]
15. Neuroprotective and symptomatic effects of targeting group III mGlu receptors in neurodegenerative disease.
Williams CJ; Dexter DT
J Neurochem; 2014 Apr; 129(1):4-20. PubMed ID: 24224472
[TBL] [Abstract][Full Text] [Related]
16. Glutamate receptors as therapeutic targets for Parkinson's disease.
Johnson KA; Conn PJ; Niswender CM
CNS Neurol Disord Drug Targets; 2009 Dec; 8(6):475-91. PubMed ID: 19702565
[TBL] [Abstract][Full Text] [Related]
17. mGlu receptors in the treatment of Parkinson's disease and L-DOPA-induced dyskinesia.
Sebastianutto I; Cenci MA
Curr Opin Pharmacol; 2018 Feb; 38():81-89. PubMed ID: 29625424
[TBL] [Abstract][Full Text] [Related]
18. Antiparkinsonian Effects of a Metabotropic Glutamate Receptor 4 Agonist in MPTP-Treated Marmosets.
Mann E; Jackson M; Lincoln L; Fisher R; Rose S; Duty S
J Parkinsons Dis; 2020; 10(3):959-967. PubMed ID: 32250315
[TBL] [Abstract][Full Text] [Related]
19. Neuroprotection by metabotropic glutamate receptor agonists on kainate-induced degeneration of motor neurons in spinal cord slices from adult rat.
Pizzi M; Benarese M; Boroni F; Goffi F; Valerio A; Spano PF
Neuropharmacology; 2000 Mar; 39(5):903-10. PubMed ID: 10699456
[TBL] [Abstract][Full Text] [Related]
20. Distribution and roles of metabotropic glutamate receptors in the basal ganglia motor circuit: implications for treatment of Parkinson's disease and related disorders.
Rouse ST; Marino MJ; Bradley SR; Awad H; Wittmann M; Conn PJ
Pharmacol Ther; 2000 Dec; 88(3):427-35. PubMed ID: 11337032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
